Orion comments on new challenge by Sun Pharmaceutical Industries Ltd., India, of Orion's U.S. Patent covering Stalevo in the US
Company states the realisation of generic competition is neither certain nor imminent
04-Jan-2008 -
Orion Corporation has been informed that Sun Pharmaceutical Industries Ltd., India (Sun), has amended its Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking authorisation to produce and market generic versions of Stalevo® tablets (25/100/200 and ...
certifications
food
Novartis
+3